INOZYME PHARMA INC's ticker is INZY and the CUSIP is 45790W108. A total of 51 filers reported holding INOZYME PHARMA INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,373,068 | -24.6% | 326,921 | 0.0% | 0.37% | 0.0% |
| Q2 2023 | $1,820,950 | +36.0% | 326,921 | +39.9% | 0.37% | +5.5% |
| Q1 2023 | $1,339,261 | +453.4% | 233,728 | +1.4% | 0.35% | +452.4% |
| Q4 2022 | $242,025 | -86.3% | 230,500 | -65.1% | 0.06% | -85.0% |
| Q3 2022 | $1,772,000 | -44.1% | 661,144 | -0.6% | 0.42% | -52.3% |
| Q2 2022 | $3,172,000 | +163.0% | 664,980 | +125.4% | 0.88% | +171.9% |
| Q1 2022 | $1,206,000 | -41.6% | 294,980 | -2.5% | 0.32% | -13.8% |
| Q4 2021 | $2,064,000 | -44.5% | 302,615 | -5.6% | 0.38% | -34.8% |
| Q3 2021 | $3,717,000 | – | 320,724 | – | 0.58% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Pivotal bioVenture Partners Investment Advisor LLC | 1,591,154 | $18,441,000 | 6.52% |
| CHI Advisors LLC | 920,264 | $10,666,000 | 3.11% |
| Sofinnova Investments, Inc. | 2,028,308 | $23,508,000 | 1.39% |
| MPM BioImpact LLC | 320,724 | $3,717,000 | 0.58% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,344,786 | $27,176,000 | 0.53% |
| NEA Management Company, LLC | 2,444,379 | $28,330,000 | 0.34% |
| Rock Springs Capital Management LP | 850,015 | $9,852,000 | 0.21% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 986,400 | $11,432,000 | 0.19% |
| Overbrook Management Corp | 16,726 | $194,000 | 0.04% |
| Orbimed Advisors | 294,000 | $3,407,000 | 0.04% |